

Special Issue

Application of Viral Vectors for Vaccine Development

Message from the Guest Editor

In the quest to develop novel vaccines, DNA, mRNA, and viral vector platforms have been employed. Both traditional and genetically engineered vaccines have contributed to the control of infectious disease pandemics, such as COVID-19. However, viral vectors, which can induce robust responses, have attracted increased attention in recent years. Viral vector vaccines have been applied in both pre-clinical and clinical trials as vaccines against a variety of infectious diseases, such as HIV-1, and SARS-CoV-2, etc. This Special Issue will provide a platform through which to discuss provision of enhanced vaccine designs, research works, and experimental results regarding the development of viral vector vaccines for both infectious and non-infectious diseases. We are pleased to invite you to contribute to this Special Issue with original research articles and reviews that focusing topics that include the following:

- Viral vector vaccine development and efficacy evaluation
- Vaccine technology
- Cancer vaccine
- Multiple vaccine technological platforms
- Protective mechanisms
- Immune response to vaccines

Guest Editor

Prof. Dr. Fei Guo

Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Deadline for manuscript submissions

closed (1 May 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/171072

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).